Rxivist logo

Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine

By Qiang Liu, Juan Hu, Jin Wang, Xin Wei, Conghui Ping, Yue Gao, Chang Xie, Ye Yu, Dongdong Li, Jing Yao

Posted 22 Sep 2020
bioRxiv DOI: 10.1101/2020.09.21.306316

The multimodal sensory channel transient receptor potential vanilloid-3 (TRPV3) is expressed in epidermal keratinocytes and implicated in chronic pruritus, allergy, and inflammation-related skin disorders. Gain-of-function mutations of TRPV3 cause hair growth disorders in mice and Olmsted Syndrome in human. Nevertheless, whether and how TRPV3 could be therapeutically targeted remains to be elucidated. We here report that mouse and human TRPV3 channel is selectively targeted by the clinical medication dyclonine that exerts a potent inhibitory effect. Accordingly, dyclonine rescued cell death caused by gain-of-function TRPV3 mutations and suppressed pruritus symptoms in vivo in mouse model. At the single-channel level, dyclonine inhibited TRPV3 open probability but not the unitary conductance. By molecular docking and mutagenesis, we further uncovered single residues in TRPV3 pore region that could toggle the inhibitory efficiency of dyclonine. The functional and mechanistic insights obtained on dyclonine-TRPV3 interaction will help to conceive updated therapeutics for skin inflammation.

Download data

  • Downloaded 194 times
  • Download rankings, all-time:
    • Site-wide: 135,082
    • In biochemistry: 4,104
  • Year to date:
    • Site-wide: 83,633
  • Since beginning of last month:
    • Site-wide: 108,129

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide